Kasper’s €315,000 CAR-T Fight: A Lifeline Out of Reach
For 4-year-old Kasper from Roosdaal, Belgium, the best hope for survival lies in a hospital in Rome — but the €315,000 price tag places it beyond the reach of his family and outside the coverage of Belgium’s public healthcare system. Diagnosed with neuroblastoma, a rare and aggressive childhood cancer, in November 2024, Kasper has already endured intensive chemotherapy, multiple surgeries, and two stem cell transplants. Now, his family is turning to crowdfunding to access a cutting-edge treatment that could save his life.
The Promise of CAR-T Cell Therapy
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a form of immunotherapy that reprograms a patient’s own immune cells to recognize and attack cancer. Unlike chemotherapy, which targets both healthy and cancerous cells, CAR-T offers a personalized, precision approach. At the Bambino Gesù Children’s Hospital in Rome, a pioneering GD2 CAR-T program has shown remarkable results. According to a study published in Nature Medicine in August 2025, 40% of children achieved complete remission six months after infusion, while patients with low disease burden saw a 77% overall response rate. Among children whose T-cells were collected at diagnosis — before chemotherapy — five-year survival reached 100%.
“The data published today tell us that this is the right path and that we are ever closer to making this therapy an integral part of standard care,” said Prof. Dr. Franco Locatelli, who leads the center’s clinical studies in hematology, oncology and cellular therapies.
A Treatment Out of Reach
Despite these promising results, CAR-T therapy for neuroblastoma is not reimbursed by Belgium’s RIZIV/INAMI health insurance system. Currently, CAR-T is covered only for specific blood cancers — children and young adults with acute lymphoblastic leukemia, and adults with diffuse large B-cell lymphoma. For solid tumors like Kasper’s neuroblastoma, the therapy remains classified as experimental, leaving families to bear the full cost.
Without reimbursement, the total cost of Kasper’s treatment trajectory — including the therapy itself, travel to Rome, accommodation, and long-term medical follow-up abroad — is estimated at €300,000 to €315,000. As reported by Editiepajot, the family and a team of volunteers launched the “Kasper zoekt helden” (Kasper Seeks Heroes) crowdfunding campaign through the Kinderkankerfonds (Children’s Cancer Fund) to raise the necessary funds.
“There is nothing as painful as having to go public with your story in such a difficult period to ask others for financial help,” Kasper’s mother Inge told local media. “That is a reality that as a parent you can barely process.”
Community Rallies Around Kasper
The campaign has sparked an outpouring of solidarity. As of late May 2026, over €77,000 had been raised — still far short of the €300,000 goal. The Kinderkankerfonds campaign page details the family’s journey and offers ways to contribute. A highlight of the fundraising efforts came on April 3, when Stéphanie Verhelst completed the Marathon des Sables — a grueling 272-kilometer race through the Moroccan desert — in support of Kasper. A major benefiet weekend is planned for June 19–21 in Onze-Lieve-Vrouw-Lombeek, featuring music, children’s activities, sports, and community events.
“No one can take over the process that Kasper and we have to go through,” said Maarten, Kasper’s father. “But that so many people carry the story around us is incredibly heartwarming. We truly feel supported.”
The family’s ordeal is compounded by a prior battle with cancer: Kasper’s older sister Willeke, now 13, was diagnosed with a brain tumor four years ago and successfully completed treatment.
A Broader Healthcare Challenge
Kasper’s case highlights a fundamental tension in Belgium’s healthcare system. While the country offers broad public health coverage through RIZIV/INAMI, innovative and expensive treatments often face long delays before reimbursement approval. Prof. Dr. Sébastien Anguille, head of hematology at UZA (University Hospital Antwerp), noted in a MagUZA interview that earlier administration of CAR-T therapy could yield even better outcomes, but current reimbursement policies restrict it to patients who have exhausted other options.
Efforts are underway to address this. UZA is working on producing CAR-T cells locally in Belgium, which could significantly reduce costs and expand access. But these initiatives remain in clinical trial stages, offering little immediate relief for families like Kasper’s.
What’s Next
For Kasper, time is of the essence. His family continues to push toward the fundraising goal, hoping to secure the treatment that offers their son the best chance at a future. The case has also reignited debate over whether Belgium should expedite reimbursement for CAR-T therapies that show strong clinical evidence — particularly for pediatric cancers where the potential for cure is highest.
As Inge put it simply: “We live entirely on hope.”